What does this research mean for the field?

The dual SGLT1/2 inhibitor sotagliflozin exerts anticancer effects in breast and lung cancer cells and modulates the expression of epigenetic regulators, including DNMT1 and class I/II HDACs. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the anticancer properties of the dual SGLT1/2 inhibitor sotagliflozin in breast and lung cancer cells, focusing on its modulation of epigenetic regulators.

September 3, 2026Cell Biology International

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells

View Full Paper

Ask AI

Bookmark

Authors

PHP. K. Hima KAK. Aswathy GDGovinda Rao DuddukuriCentral University of Kerala

Discussion

Member takes

Implication

In vitro study demonstrates that sotagliflozin suppresses growth and alters epigenetic regulators in breast and lung cancer cells, indicating potential repurposing for oncology.

Key Points

To investigate the anticancer properties of the dual SGLT1/2 inhibitor sotagliflozin in breast and lung cancer cells, focusing on its modulation of epigenetic regulators.
Treated human breast (MCF-7) and lung (A549) cancer cell lines with sotagliflozin to assess cell viability, clonogenic survival, migration, and invasion.
Performed molecular docking simulations to evaluate the binding affinity of sotagliflozin to DNA methyltransferases (DNMT1, DNMT3A, DNMT3B).
Measured total DNMT activity, DNMT1 and class I/II HDAC expression, metabolic signaling proteins (AMPK, PTEN-AKT-mTOR), and autophagy markers.
Sotagliflozin significantly decreased viability, clonogenic survival, migration, and invasion in both cell lines while inducing G2/M arrest and activating AMPK signaling.
Molecular docking predicted strong binding of sotagliflozin to DNMT1 (-8.9 kcal/mol), consistent with observed reductions in DNMT activity, DNMT1 expression, and class I/II HDAC levels (HDAC1-4 and HDAC6).
Treatment stimulated autophagy, marked by an increase in acidic vesicular organelles and elevated LC3-II and Beclin-1 protein expression.

Cite This Study

Hima et al. (2026) studied this question.

synapsesocial.com/papers/6a99352e636c6408cfa7d307 https://doi.org/10.1002/cbin.70201

View Full Paper

Ask AI

Bookmark

Implication

In vitro study demonstrates that sotagliflozin suppresses growth and alters epigenetic regulators in breast and lung cancer cells, indicating potential repurposing for oncology.

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider